Article

FDA Approvals and Breakthroughs Highlight Specialty Pharmacy Week in Review

Author(s):

Davy James, Managing Editor

Top stories of the week on Specialty Pharmacy Times.

[<a href="//storify.com/pharmacytimes/fda-approvals-and-breakthroughs-highlight-specialt" target="_blank">View the story "FDA Approvals and Breakthroughs Highlight Specialty Pharmacy Week in Review" on Storify</a>]

Related Videos
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Naloxone concept represented by wooden letter tiles.
Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication
Related Content
Hidradenitis Suppurative, FDA, Dermatology, Bimzelx | Image Credit: © Gorodenkoff | stock.adobe.com
Published: November 20th 2024 | Updated: November 20th 2024

FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa

Ashley Gallagher, Associate Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Associate Editor
Diversity, Pharmacy, Student Exchange, Pharmacy Student | Image Credit: © Studio Romantic | stock.adobe.com
November 13th 2024

Student Exchange Program Crafts Cultural Competency for Pharmacists

Rena Reid, PharmD
Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations
January 25th 2024

Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations

Diabetes, Cagrilintinide, Semagliutide | Image Credit: millaf - stock.adobe.com
November 11th 2024

An Overlook of Cagrilintinide and Semaglutide as it Progresses Through Phase 3 Trials

Vidhi Patel, PharmD Candidate
Spinal health visualization Individual suffering spinal muscular dystrophy glowing depiction of progressive muscle weakness affecting the spine
November 8th 2024

FDA Grants Orphan Drug Designation to Ifetroban for Treatment of Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Luke Halpern, Assistant Editor